Abstract:
:Breast cancer survivors are at an increased risk of second primary cancers, and the risk factors for the latter may have clinical significance. The aims of our study were to evaluate the incidences and risk factors of second primary female genital cancers (corpus uteri, cervix uteri plus ovary) in a large cohort of breast cancer survivors. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined the standardized incidence ratio (SIR) and risk factors for second primary female genital cancers observed between 2000 and 2014. Breast cancer survivors had increased SIRs for second corpus uteri cancers and second ovarian cancers and a decreased SIR for second cervical cancers (SIR 1.17, 1.12, and 0.64, respectively). Risk factors of second corpus uteri cancers were the age at first cancer diagnosis, race (black vs. white, aHR = 1.142 95% CI 1.005-1.298), and progesterone receptor (PR) status (PR+ vs. PR-, aHR = 1.131 95% CI 1.004-1.273). In addition, the risk of second ovarian cancer was positively associated with age while inversely associated with race (black vs. white, aHR = 0.691 95% CI 0.555-0.859) and estrogen receptor (ER) status (ER+ vs. ER-, aHR = 0.655 95% CI 0.544-0.788). Age, race, and hormone receptor status are risk factors of developing second female genital cancers among breast cancer survivors. Older age, black race, and a PR+ status in survivors are associated with a higher risk of second corpus uteri cancers. Additionally, older age and an ER- status should increase vigilance for potential second ovarian cancers.
journal_name
Horm Cancerjournal_title
Hormones & cancerauthors
Li Z,Wu Q,Song J,Zhang Y,Zhu S,Sun Sdoi
10.1007/s12672-018-0330-0subject
Has Abstractpub_date
2018-06-01 00:00:00pages
197-204issue
3eissn
1868-8497issn
1868-8500pii
10.1007/s12672-018-0330-0journal_volume
9pub_type
杂志文章abstract::Castration-resistant prostate cancer (CRPC) is an androgen receptor (AR)-dependent disease expected to cause the death of more than 27,000 Americans in 2015. There are only a few available treatments for CRPC, making the discovery of new drugs an urgent need. We report that CUDC-101 (an inhibitor od HER2/NEU, EGFR and...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-016-0257-2
更新日期:2016-06-01 00:00:00
abstract::Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity contributing to approximately 8,200 annual deaths in the USA. Despite advances to the understanding of endometrial cancer, novel interventions for the disease are necessary given that many tumors become refractory to ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-013-0157-7
更新日期:2013-12-01 00:00:00
abstract::Evidence has not been established to support that combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) improves survival in patients with malignant pheochromocytoma and paraganglioma (M-PPGL). To investigate the efficacy of CVD for this disease, we retrospectively analyzed data of 23 pati...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0284-7
更新日期:2017-04-01 00:00:00
abstract::Small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) is a steroid receptor molecular co-chaperone that may substantially influence hormone action and, consequently, hormone-mediated carcinogenesis. To date, published studies describe SGTA as a protein that is potentially critical in a range of bio...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-013-0151-0
更新日期:2013-12-01 00:00:00
abstract::Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones. Previously, we found dualistic miR-204 effects, acting ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-016-0279-9
更新日期:2017-02-01 00:00:00
abstract::Ovarian cancer is the leading cause of death among gynecological malignancies. Chemotherapy alone is not sufficient to achieve long-term survival of the patient with advanced stage ovarian cancer. Although cancer immune therapy has long been expected as a new modality for ovarian cancer, very few trials have been clin...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0046-2
更新日期:2010-12-01 00:00:00
abstract::The molecular pathogenesis of sporadic parathyroid adenomas is incompletely understood. The possible role of cyclin-dependent kinase inhibitor (CDKI) genes was raised by recognition of cyclin D1 as a parathyroid oncogene, identification of rare germline mutations in CDKI genes in patients with multiple endocrine neopl...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-013-0147-9
更新日期:2013-10-01 00:00:00
abstract::Von Hippel-Lindau (VHL) syndrome is an inherited cancer syndrome in which 8-17 % of germline mutation carriers develop pancreatic neuroendocrine tumors (PNETs). There is limited data on prognostic markers for PNETs other than Ki-67, which is included in the World Health Organization classification system. Recently, sp...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-013-0134-1
更新日期:2013-06-01 00:00:00
abstract::Breast and prostate cancers are malignancies in which steroid hormones drive cellular proliferation. Over the past century, this understanding has led to successful treatment strategies aimed to inhibit hormone-mediated tumor growth. Nonetheless, disease relapse and progression still pose significant clinical problems...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-016-0259-0
更新日期:2016-06-01 00:00:00
abstract::Mitotic checkpoint is a fundamental mechanism involved in fidelity mitotic chromosome segregation, and its alteration results in progression of human malignancies. In this study, we examined expression profiles of seven mitotic checkpoint genes in 20 breast carcinomas using microarray analysis. Results demonstrated th...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-012-0130-x
更新日期:2013-04-01 00:00:00
abstract::Recent observations connected DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. We addressed whether APOBEC3B is associated with breast cancer clinical outcomes. APOBEC3B messenger RNA (mRNA) levels were related in 1,491 primary breast cancers to disease-free (DFS), metastasis-free (MFS), and ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0196-8
更新日期:2014-12-01 00:00:00
abstract::Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenes...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-015-0241-2
更新日期:2016-02-01 00:00:00
abstract::The anti-diabetic drug metformin (1,1-dimethylbiguanide hydrochloride) reduces both the incidence and mortality of several types of cancer. Metformin has been shown to selectively kill cancer stem cells, and triple-negative breast cancer (TNBC) cell lines are more sensitive to the effects of metformin as compared to l...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0188-8
更新日期:2014-12-01 00:00:00
abstract::Lymphangioleiomyomatosis (LAM) is a female-predominant lung disease that can lead to respiratory failure. LAM cells typically have inactivating tuberous sclerosis 2 (TSC2) mutations, leading to mTORC1 hyperactivation. The gender specificity of LAM suggests that female hormones contribute to disease progression. Clinic...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0192-z
更新日期:2014-10-01 00:00:00
abstract::We previously reported that an accelerated decline in circulating testosterone level is associated with a higher risk of prostate cancer (PCa). This study is to examine whether testosterone change rate is related to serum prostate-specific antigen (PSA) concentration among PCa-free men. Longitudinal data were derived ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-019-00369-y
更新日期:2019-12-01 00:00:00
abstract::Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen ...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-019-0358-9
更新日期:2019-06-01 00:00:00
abstract::CYP19A1, also called aromatase, is a key enzyme for converting androgens to estrogens of estrogen synthesis. Elevated serum estrogen and high expression levels of estrogen-related proteins are found in cholangiocarcinoma (CCA; bile duct cancer). However, the expression of CYP19A1 in relation to estrogen-related protei...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0349-2
更新日期:2018-12-01 00:00:00
abstract::Silent corticotrophins adenomas (SCAs) are clinically silent and non-secreting but immunostain positively for ACTH. We hypothesize that SCAs comprise both corticotroph and gonadotroph characteristics. Cohort analysis from 1994-2008 with follow-up time ranging from 1-15 years in a tertiary referral center. We compared ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0014-x
更新日期:2010-04-01 00:00:00
abstract::Genetic variants in CYP19A1, the gene encoding aromatase, have been reported to be associated with circulating estrogen concentrations, a key risk factor for breast cancer. The mechanism underlying this association is still unclear; it has been suggested that some of these variants may alter the expression and/or acti...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0317-2
更新日期:2018-04-01 00:00:00
abstract::Differential utilization of cancer screening between populations could lead to changes in cancer disparities. Evaluating incidence rates trends is one means of monitoring these disparities. Using Surveillance, Epidemiology, and End Results data, we compared annual percent changes (APC) in age-adjusted incidence rates ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-009-0002-1
更新日期:2010-02-01 00:00:00
abstract::Residential characteristics in urban neighborhoods impact health and might be important factors contributing to health disparities, especially in the African American population. The purpose of this systematic review is to understand the relationship between urban neighborhood and residential factors and breast cancer...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0325-x
更新日期:2018-04-01 00:00:00
abstract::Oestrogen receptor alpha (ERα) is a ligand-dependent transcription factor that mediates oestrogen effects in hormone-responsive cells. Following oestrogenic activation, ERα directly regulates the transcription of target genes via DNA binding. MicroRNAs (miRNAs) represent a class of small noncoding RNAs that function a...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-012-0102-1
更新日期:2012-06-01 00:00:00
abstract::Consumption of methylxanthine alkaloids appears to induce activities by antagonizing adenosine receptors, implicated in breast cancer behavior in vitro. Our goal was to evaluate expression of genes for methylxanthine receptors and metabolizing enzymes to assess risk of breast carcinoma recurrence. Clinical outcomes, e...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0309-2
更新日期:2017-12-01 00:00:00
abstract::Cancer-associated fibroblasts have been shown to inhibit or stimulate tumor growth depending on stage, grade, and tumor type. It remains unclear, however, the effect of endometrial-cancer-associated fibroblasts on hormone-driven responses in endometrial cancer. In this study, we investigated the effect of normal and c...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-015-0223-4
更新日期:2015-08-01 00:00:00
abstract::Adjuvant glucocorticoid treatment is routinely used in the treatment of ovarian cancer to mitigate the undesirable side effects of chemotherapy, thereby enhancing tolerability to higher cytotoxic drug doses and frequency of treatment cycles. However, in vitro and preclinical in vivo and ex vivo studies indicate that g...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-017-0319-0
更新日期:2018-04-01 00:00:00
abstract::Thyroid hormone status has long been implicated in cancer development. Here we investigated the role of thyroxine (T4) in colorectal cancer cell lines HCT 116 (APC wild type) and HT-29 (APC mutant), as well as the primary cultures of cancer cells derived from patients. Cell proliferation was evaluated with standard as...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0324-y
更新日期:2018-06-01 00:00:00
abstract::In hepatocellular carcinoma (HCC), the hypoxic tumor microenvironment can drive enhance tumor malignancy and recurrence. The microRNA (miRNA) miR-196-5p has been shown to modulate the progression of several cancer types, but its roles in HCC remain uncertain. In the present report we observed significant miR-196-5p do...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-019-00370-5
更新日期:2019-12-01 00:00:00
abstract::The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), polycyclic aromatic hydrocarbons (PAHs), benzene, and polychlorinated biphenyls (PCBs) through the initi...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-017-0300-y
更新日期:2017-08-01 00:00:00
abstract::The authors conducted a cross-sectional study to investigate the associations of fat, fiber, and carbohydrate intake with endogenous estrogen, androgen, and insulin-like growth factor (IGF) levels among 595 premenopausal women. Overall, no significant associations were found between dietary intake of these macronutrie...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0050-6
更新日期:2010-10-01 00:00:00
abstract::The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in p...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-014-0207-9
更新日期:2015-02-01 00:00:00